Cinaciguat (BAY 58–2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure
- 2 June 2009
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 119 (21), 2781-2788
- https://doi.org/10.1161/circulationaha.108.800292
Abstract
Background— Cinaciguat (BAY 58–2667) is the first of a new class of soluble guanylate cyclase activators in clinical development for acute decompensated heart failure. We aimed to assess the hemodynamic effects, safety, and tolerability of intravenous cinaciguat in patients with acute decompensated heart failure (pulmonary capillary wedge pressure ≥18 mm Hg). Methods and Results— After initial dose finding (part A; n=27), cinaciguat was evaluated in the nonrandomized, uncontrolled proof-of-concept part of the study (part B; n=33) using a starting dose of 100 μg/h, which could be titrated depending on hemodynamic response. Patients were categorized as responders if their pulmonary capillary wedge pressure decreased by ≥4 mm Hg compared with baseline. Final doses of cinaciguat after 6 hours of infusion in part B were 50 μg/h (n=2), 200 μg/h (n=12), and 400 μg/h (n=16). Compared with baseline, a 6-hour infusion of cinaciguat led to significant reductions in pulmonary capillary wedge pressure (−7.9 mm Hg), mean right atrial pressure (−2.9 mm Hg), mean pulmonary artery pressure (−6.5 mm Hg), pulmonary vascular resistance (−43.4 dynes · s · cm −5 ), and systemic vascular resistance (−597 dynes · s · cm −5 ), while increasing heart rate by 4.4 bpm and cardiac output by 1.68 L/min. The responder rate was 53% after 2 hours, 83% after 4 hours, and 90% after 6 hours. Cinaciguat was well tolerated, with 13 of 60 patients reporting 14 drug-related treatment-emergent adverse events of mild to moderate intensity, most commonly hypotension. Conclusions— Cinaciguat has potent preload- and afterload-reducing effects, increasing cardiac output. Further investigation of cinaciguat for acute decompensated heart failure is warranted.This publication has 23 references indexed in Scilit:
- Targeting Heme-Oxidized Soluble Guanylate CyclaseHypertension, 2007
- NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialNature Reviews Drug Discovery, 2006
- Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillationHeart, 2005
- Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)European Heart Journal, 2005
- Acute Decompensated Heart Failure: A Contemporary Approach to Pharmacotherapeutic ManagementPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Long-Term Trends in the Incidence of and Survival with Heart FailureThe New England Journal of Medicine, 2002
- The Burden of Chronic Congestive Heart Failure in Older Persons: Magnitude and Implications for Policy and ResearchHeart Failure Reviews, 2002
- The heart failure epidemic: exactly how big is it?European Heart Journal, 2001
- cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase.Proceedings of the National Academy of Sciences of the United States of America, 1996
- Trends in hospitalization for heart failure in Scotland 1980-1990European Heart Journal, 1993